Tag: medical marijuana


Today in Cannabis

New York legislatures have passed “The Compassionate Care Act”, allowing the states’ citizens legal access to cannabis-based medicines.



The National Cannabis Industry Association (NCIA) has attracted national attention preparing for Denver’s Cannabis Business Summit, scheduled for June 24th & 25th.



Today in Cannabis

The latest trend following the infusion of oils with cannabis, has been the implementation of comprehensive spa treatments.



Proposed changes to New Mexico’s current medical cannabis policies would allow for expansion and more reliable access to medicine for a growing number of patients.



Floridans will have a chance to decide in November if the recently approved ‘Charlotte’s Web’ legislation will be expanded to include all forms of the whole cannabis plant.



Today in Cannabis

Ambiguity in cannabis laws causes confusion for Colorado businesses. Legal purchasing begs the question, where exactly can consumers smoke?


The crime rate in Denver has significantly declined since legalization. Still, robberies target dispensaries due to large amounts of cash on the shops’ premises. Since cannabis is still federally illegal, the new outcry of injustice is directed at the Federal Reserve. Once cannabis commerce is embraced federally, there will be much less incentive for these crimes.



As cannabis commerce grows exponentially, ancillary business opportunities naturally appear. Food safety has been the talk recently; as the edible industry gains popularity, people want to know more about how products are infused and where ingredients come from…beyond the medicine they contain.





Co-Ops for Grow-Ops

As cannabis is still only legal in 22 states and the District of Columbia, federal banks have avoided dealing with cannabis businesses in order to stay out of federal courtrooms. This is one of the industry’s largest pitfalls; the lack of financial regulation, combined with the (now federally-recognized) tolerance of the industry, has fostered circumstances which leave much to the imagination about how cash is handled once transactions are complete.

The ultimate solution is still up for debate, however the first break for establishments in CO was signed into law by Governor John Hickenlooper on Friday: HB 1398. The bill allows for the formation of what it refers to as “marijuana financial service cooperatives” or “credit co-ops”. Dispensaries currently operating as cash-only businesses, suffer due to increased costs of business and risk for criminal activity (due to “large amounts of cash on the premises”).



Today in Cannabis

My Compassion, a nonprofit organization, prepares for the Chicago Cannabis Conference on Navy Pier this weekend. The first conference of its kind, speakers include: state representatives, doctors, lawyers, and industry professionals advocating the forward movement of responsibility and professionalism in a previously forbidden realm.


The UK-based GW pharmaceuticals has announced plans to implement their product Epidiolex in US markets. Epidiolex is a cannabidiol (CBD) extract used to treat childhood epilepsy resulting from Dravet syndrome. Currently, Epidiolex is in use by only seven patients in the US under unique legal circumstances. As of today, the United States’ FDA has approved Epidiolex for “fast track designation”, which expedites the availability of breakthrough treatments.





Today in Cannabis

For over a decade, synthetic “herbal incense” designed to mimic the effects of cannabis has gained popularity due to the fact it’s been buyable in-store, and doesn’t show up on drug tests. It’s dangerous because synthetic cannabanoids have the potential to be much more potent than their organic counterparts. In addition, their non-regulation leaves much unknown about potential negative effects.

The reason volatile ‘analogs’ (like various versions of herbal incense) even exist, is cannabis prohibition. If the federal government doesn’t make serious amendments to drug policy, significant demand for herbal incense will remain.



Today in Cannabis

Republican Governor Terry Branstad signed a bill, the Medical Cannabidiol Act (SF 2360), allowing regulated CBD medications for children in Iowa. As the medical potential for CBD raises attention across the nation, parents in need of new options for their children are pressing lawmakers to get bills like the Medical Cannabidiol Act signed in their respective states.

Pictured above is Jayden David; he has a severe seizure-causing disorder called Dravet syndrome. His father was one of the first people to publicize this controversial, but ultimately life-saving, decision to treat his son with CBD oil extract. Their story has become synonymous with the success of CBD treatment, and can be followed on their Facebook page: Jason and Jayden’s Journey.



Redefining ‘Essential’ Oils

Colorado continues to lead the charge in medical advancement related to non-psychoactive components of the cannabis plant; cases such as those of Charlotte Figi  (pictured above) have inspired action elsewhere in the country.

North Carolina Governor Pat McElraft proposed a bill Tuesday: “Hope 4 Haley and Friends” (H.B. 1220). This legislation would allow medical regulation of CBD (an essential oil naturally occurring in cannabis resin glands) in the Tar Heel state, for children suffering from severe seizure-causing disorders. Despite her anti-legalization perspective, the Republican Governor boldly advocates this bill; for North Carolinians without the resources to pick up and move to a medical state such as Colorado, H.B. 1220 is currently the only ray of hope as far as obtaining legal and regulated medicine that could potentially save children’s lives.



Back on Schedule

Virginia congressman Morgan Griffith presented HR 4498 earlier this month. “The Legitimate Use of Medicinal Marijuana Act” aims to federally reclassify cannabis from Schedule I to II. Before considering the disproportion related to legal consequence, only substances which have no medical value are placed under Schedule I; the key to this bill is security for medical establishments on a federal level.